A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure

Mahesh SwaminathanDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Gautam BorthakurDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA;

Tapan M. KadiaDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Alessandra FerrajoliDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Yesid AlvaradoDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Naveen PemmarajuDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Kristy BoddenDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Brittany YearbyDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Marina KonoplevaDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Joseph KhouryDepartment of Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, TX, USAView further author information

Carlos Bueso-RamosDepartment of Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, TX, USAView further author information

Guillermo Garcia-ManeroDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; View further author information

Courtney D. DiNardoDepartment of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
View further author information

References